Latest & greatest articles for cannabis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cannabis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cannabis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cannabis

41. Epidemiology of cannabis use among older people: a review

Epidemiology of cannabis use among older people: a review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2019 PROSPERO

42. On the face of it: A systematic review of the labelling of cannabis and cannabinoid products in regulated markets: Is what's on the label what's in the product?

On the face of it: A systematic review of the labelling of cannabis and cannabinoid products in regulated markets: Is what's on the label what's in the product? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

43. Pharmacokinetics and pharmacodynamics of medical cannabis: a systematic review of the literature

Pharmacokinetics and pharmacodynamics of medical cannabis: a systematic review of the literature Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

44. Effects of cannabis on cognitive function in older adults

Effects of cannabis on cognitive function in older adults Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2019 PROSPERO

45. The Association between Maternal Cannabis Exposure during Pregnancy and/or Breastfeeding and Physical and Socio-behavioural Health Outcomes during Prenatal Period, Infancy (0-2 years old), and Early Childhood (3-5 years old): An Overview of Systematic Rev

The Association between Maternal Cannabis Exposure during Pregnancy and/or Breastfeeding and Physical and Socio-behavioural Health Outcomes during Prenatal Period, Infancy (0-2 years old), and Early Childhood (3-5 years old): An Overview of Systematic Rev Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied

2019 PROSPERO

46. Benefit/risk ratios of therapeutic cannabis and cannabinoids: a systematic review and meta-analysis of randomised controlled trials

Benefit/risk ratios of therapeutic cannabis and cannabinoids: a systematic review and meta-analysis of randomised controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

47. Cannabis exposure in youth and cognitive trajectories

Cannabis exposure in youth and cognitive trajectories Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

48. Cannabis

Cannabis This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. © The Author(s) 2018. Published by Oxford University Press on behalf of the Canadian Association of Gastroenterology. 1 Received: October 10, 2018; Accepted: October 17, 2018 Original Article Canadian Association (...) of Gastroenterology Position Statement: Use of Cannabis in Gastroenterological and Hepatic Disorders Christopher N. Andrews MD, MSc 1 , Shane M. Devlin MD 1 , Bernard Le Foll MD, PhD 2,3,4,5 , Benedikt Fischer PhD 6 , Frances Tse MD, MPH 7 , Martin Storr MD 8 , Stephen E. Congly MD, MSc 1 1 Division of Gastroenterology and Hepatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; 2 T ranslational Addiction Research Laboratory, Campbell Family Mental Health Research Institute, Centre

2018 Canadian Association of Gastroenterology

49. Cannabis for the treatment of ulcerative colitis. (PubMed)

Cannabis for the treatment of ulcerative colitis. Cannabis and cannabinoids are often promoted as treatment for many illnesses and are widely used among patients with ulcerative colitis (UC). Few studies have evaluated the use of these agents in UC. Further, cannabis has potential for adverse events and the long-term consequences of cannabis and cannabinoid use in UC are unknown.To assess the efficacy and safety of cannabis and cannabinoids for the treatment of patients with UC.We searched (...) MEDLINE, Embase, WHO ICTRP, AMED, PsychINFO, the Cochrane IBD Group Specialized Register, CENTRAL, ClinicalTrials.Gov and the European Clinical Trials Register from inception to 2 January 2018. Conference abstracts and references were searched to identify additional studies.Randomized controlled trials (RCTs) comparing any form or dose of cannabis or its cannabinoid derivatives (natural or synthetic) to placebo or an active therapy for adults (> 18 years) with UC were included.Two authors

2018 Cochrane

50. Cannabis for the treatment of Crohn's disease. (PubMed)

Cannabis for the treatment of Crohn's disease. Crohn's disease (CD) is a chronic immune-mediated condition of transmural inflammation in the gastrointestinal tract, associated with significant morbidity and decreased quality of life. The endocannabinoid system provides a potential therapeutic target for cannabis and cannabinoids and animal models have shown benefit in decreasing inflammation. However, there is also evidence to suggest transient adverse events such as weakness, dizziness (...) and diarrhea, and an increased risk of surgery in people with CD who use cannabis.The objectives were to assess the efficacy and safety of cannabis and cannabinoids for induction and maintenance of remission in people with CD.We searched MEDLINE, Embase, AMED, PsychINFO, the Cochrane IBD Group Specialized Register, CENTRAL, ClinicalTrials.Gov, and the European Clinical Trials Register up to 17 October 2018. We searched conference abstracts, references and we also contacted researchers in this field

2018 Cochrane

51. Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies

Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies This review examines evidence for the effectiveness of cannabinoids in chronic noncancer pain (CNCP) and addresses gaps in the literature by: considering differences in outcomes based on cannabinoid type and specific CNCP condition; including all study designs; and following IMMPACT guidelines. MEDLINE, Embase, PsycINFO

2018 EvidenceUpdates

52. Growing at Home: Health and Safety Concerns for Personal Cannabis Cultivation

Growing at Home: Health and Safety Concerns for Personal Cannabis Cultivation GROWING AT HOME: HEALTH AND SAFETY CONCERNS FOR PERSONAL CANNABIS CULTIVATION PURPOSE Personal cultivation as described by the proposed Cannabis Act (2017) 1 will permit adults to cultivate up to four canna- bis plants per household. This provision is intended to both promote equity by facilitating access to legal cannabis, par- ticularly when retail outlets are difficult to access, and to undercut the black market (...) . However, indoor cultivation and processing of cannabis may also introduce or exacerbate certain environmental health risks in the home. This document identifies health and safety concerns that may be relevant to personal cultivation after legalization – that is, legal home growing and the associated health risks. Although this information may be of relevance to the public at large, the evidence presented here has been synthesized and organized for policy- and decision-makers, environmen- tal

2018 National Collaborating Centre for Environmental Health

53. Clearing the Smoke on Cannabis: Maternal Cannabis Use during Pregnancy ? An Update

Clearing the Smoke on Cannabis: Maternal Cannabis Use during Pregnancy ? An Update Key Points • Cannabis is the illicit drug most commonly used during pregnancy. • Constituents of cannabis can pass into breast milk during lactation and are absorbed and metabolized by the infant. • Frequent cannabis use during pregnancy is associated with low birth weight and is part of a cluster of risk-factors correlated with other adverse birth outcomes. • Prenatal and early exposure to cannabis can alter (...) neurodevelopment leading to adverse effects on cognition and academic achievement. • There are also effects on behaviour in children and young adults, including attention deficits, increased hyperactivity and impulsivity, and increased likelihood of substance use. • Information on the effects of cannabis use during pregnancy is essential to help healthcare providers advise patients about the impact of cannabis use and improve the health and well-being of patients and their children. Background After alcohol

2018 Canadian Centre on Substance Abuse

54. Cannabis

Cannabis Top results for cannabis - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for cannabis The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

55. Cannabis

Cannabis www.ccsa.ca • www.ccdus.ca June 2018 Canadian Drug Summary Canadian Centre on Substance Use and Addiction • Centre canadien sur les dépendances et l’usage de substances Page 1 Cannabis Introduction Cannabis, more commonly called marijuana, is a tobacco-like greenish or brownish material consisting of the dried flowers, fruiting tops and leaves of the cannabis plant, Cannabis sativa. Hashish or cannabis resin is the dried brown or black resinous secretion of the flowering tops (...) of the cannabis plant and can be further processed to produce hash oil, wax or shatter. There is preliminary evidence of higher risks of resins due to the higher concentrations of THC. Cannabis is usually smoked as a cigarette (“joint”) or smoked as resins in a pipe or bong, also known as “dabbing.” 1 Vaporizers are also used to reduce the toxins inhaled from cannabis smoke. Some individuals who use cannabis slice open and hollow out cigars and replace the tobacco with marijuana (called “blunts”). In some

2018 Canadian Centre on Substance Abuse

56. Daily use of high-potency cannabis is associated with an increased risk of admission and more intervention after first-episode psychosis

Daily use of high-potency cannabis is associated with an increased risk of admission and more intervention after first-episode psychosis Daily use of high-potency cannabis is associated with an increased risk of admission and more intervention after first-episode psychosis | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies (...) , please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Daily use of high-potency cannabis is associated with an increased risk of admission and more intervention after

2018 Evidence-Based Mental Health

57. Therapeutic Cannabis and Endocannabinoid Signaling System Modulator Use in Otolaryngology Patients (PubMed)

Therapeutic Cannabis and Endocannabinoid Signaling System Modulator Use in Otolaryngology Patients 1) review benefits and risks of cannabis use, with emphasis on otolaryngic disease processes; 2) define and review the endocannabinoid signaling system (ESS); and 3) review state and federal regulations for the use and research of cannabis and ESS modulators.This manuscript is a review of the current literature relevant to the stated objectives.Cannabis (marijuana) use is increasing (...) . It is the most widely used illicit substance in the world. There is increasing interest in its therapeutic potential due to changing perceptions, new research, and legislation changes controlling its use. The legal classification of cannabis is complicated due to varied and conflicting state and federal laws. There are currently two synthetic cannabinoid drugs that are FDA approved. Current indications for use include chemotherapy-related nausea and vomiting, cachexia, and appetite loss. Research has

Full Text available with Trip Pro

2018 Laryngoscope investigative otolaryngology

58. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence

Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence Review evidence for cannabinoids as adjunctive treatments for treatment-resistant epilepsy. Systematic search of Medline, Embase and PsycINFO was conducted in October 2017. Outcomes were: 50%+ seizure reduction, complete seizure freedom; improved quality of life (QoL). Tolerability/safety were assessed by study withdrawals, adverse events (AEs) and serious adverse events (SAEs

Full Text available with Trip Pro

2018 EvidenceUpdates

59. Cannabis-based medicines for chronic neuropathic pain in adults. (PubMed)

Cannabis-based medicines for chronic neuropathic pain in adults. This review is one of a series on drugs used to treat chronic neuropathic pain. Estimates of the population prevalence of chronic pain with neuropathic components range between 6% and 10%. Current pharmacological treatment options for neuropathic pain afford substantial benefit for only a few people, often with adverse effects that outweigh the benefits. There is a need to explore other treatment options, with different mechanisms (...) of action for treatment of conditions with chronic neuropathic pain. Cannabis has been used for millennia to reduce pain. Herbal cannabis is currently strongly promoted by some patients and their advocates to treat any type of chronic pain.To assess the efficacy, tolerability, and safety of cannabis-based medicines (herbal, plant-derived, synthetic) compared to placebo or conventional drugs for conditions with chronic neuropathic pain in adults.In November 2017 we searched CENTRAL, MEDLINE, Embase

2018 Cochrane

60. Medical Cannabis Use in Palliative Care: Clinical Effectiveness and Guidelines

Medical Cannabis Use in Palliative Care: Clinical Effectiveness and Guidelines Medical Cannabis Use in Palliative Care: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Medical Cannabis Use in Palliative Care: Clinical Effectiveness and Guidelines Medical Cannabis Use in Palliative Care: Clinical Effectiveness and Guidelines Last updated: September 10, 2018 Project Number: RB1257-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type (...) : Report Question What is the clinical effectiveness of medical cannabis products for symptom control in adult palliative care patients? What are the evidence-based guidelines regarding medical cannabis products for symptom control in adult palliative care patients? Key Message Two systematic reviews (one with a meta-analysis), one non-randomized study, and two evidence-based guidelines were identified regarding medical cannabis products for symptom control in adult palliative care patients. Files

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review